FDA Grants Orphan Drug Designation for the Treatment of Scleroderma

NORTH CHICAGO, Ill., April 11, 2024 /PRNewswire/ — BLR Bio, an emerging biotechnology company in Rosalind Franklin University’s Helix 51 biomedical incubator, announced that the U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for its investigational therapy…